Stay updated on Clinical Trial: mRNA-1273 Dose-Confirmation Study

Sign up to get notified when there's something new on the Clinical Trial: mRNA-1273 Dose-Confirmation Study page.
Latest website image capture
Clouds background image

Latest updates to the Clinical Trial: mRNA-1273 Dose-Confirmation Study page

  1. Check
    3 days ago
    Change Detected
    Summary
    Revision updated from v3.5.0 to v3.5.2.
    Difference
    0.0%
    Check dated 2026-04-20T16:52:44.000Z thumbnail image
  2. Check
    10 days ago
    No Change Detected
  3. Check
    17 days ago
    Change Detected
    Summary
    - Deleted multiple data fields and numerical values related to immunogenicity (GMT, ID50/ID80 titers, seroconversion rates, MN titers) across the Part A, Part B, and Part C results sections.
    Difference
    4%
    Check dated 2026-04-06T08:59:10.000Z thumbnail image
  4. Check
    32 days ago
    Change Detected
    Summary
    The site's revision tag was updated from v3.4.3 to v3.5.0.
    Difference
    0.0%
    Check dated 2026-03-22T01:26:46.000Z thumbnail image
  5. Check
    48 days ago
    Change Detected
    Summary
    Revision updated from v3.4.2 to v3.4.3 on the page.
    Difference
    0.0%
    Check dated 2026-03-06T18:09:25.000Z thumbnail image
  6. Check
    55 days ago
    Change Detected
    Summary
    Added comprehensive immunogenicity results, including GMT/GM with 95% CIs and seroconversion rates for multiple antibody assays across Parts A–C and several timepoints.
    Difference
    6%
    Check dated 2026-02-27T15:21:55.000Z thumbnail image
  7. Check
    69 days ago
    Change Detected
    Summary
    Footer revision updated from v3.4.1 to v3.4.2. No changes to the study results or page content.
    Difference
    0.0%
    Check dated 2026-02-13T02:39:15.000Z thumbnail image

Stay in the know with updates to Clinical Trial: mRNA-1273 Dose-Confirmation Study

Enter your email address, and we'll notify you when there's something new on the Clinical Trial: mRNA-1273 Dose-Confirmation Study page.